Navigation Links
Gene mutation may lead to treatment for liver cancer
Date:7/8/2014

Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature.

A team led by the Icahn School of Medicine at Mount Sinai and Harvard Medical School has discovered a link between the presence of two mutant proteins IDH1 and IDH2 and cancer. Past studies have found IDH mutations to be among the most common genetic differences seen in patients with iCCA, but how they contribute to cancer development was unknown going into the current effort.

iCCA strikes bile ducts, tube-like structures in the liver that carry bile, which is required for the digestion of food. With so much still unknown about the disease, there is no first-line, standard of care and no successful therapies.

"iCCA is resistant to standard treatments like chemotherapy and radiation," said Josep Maria Llovet, MD, Director of the Liver Cancer Program, Division of Medicine, Icahn School of Medicine at Mount Sinai, and contributing author. "Understanding the molecular mechanism of the disease is the key to finding a treatment that works."

Dr. Llovet and colleagues demonstrated that the expression of mutant IDH in the adult liver of genetically engineered mice impairs liver cell development and liver regeneration a process in which the liver responds to injury and increases the number of cells to form a tumor. Moreover, mutant IDH were found to work with activated KRAS, a gene essential in cancer development, causing the development of premalignant lesions and a progression to metastatic iCCA.

"Our findings provide novel insights into the development iCCA and offers a possible treatment option for patients suffering from this fatal disease," said Dr. Llovet.

By pinpointing one pathway of iCCA, this study opens up a new line of investigation to identify biomarkers of the disease. Already, Phase 1 clinical trials are being conducted with specific IDH1/2 mutations. The hope is that results of these and future studies can help doctors make life-saving decisions for their patients.


'/>"/>

Contact: Lucia Lee
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. Researchers identify mitochondrial mutation linked to congenital myasthenic syndrome
2. Severe scoliosis linked to rare mutations
3. Newly identified brain cancer mutation will aid drug development
4. Gene mutation found for aggressive form of pancreatic cancer
5. Univ. of MD researchers identify fat-storage gene mutation that may increase diabetes risk
6. Small mutation changes brain freeze to hot foot
7. Scripps Florida scientists find connection between gene mutation, key symptoms of autism
8. Virus-fighting genes linked to mutations in cancer
9. Key genetic mutations could be new hope for adrenocortical tumor patients
10. Erasing a genetic mutation
11. Genetic mutations warn of skin cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... ... June 28, 2017 , ... Alevio, LLC ( ... the 500th case using the SiCure Sacroiliac Joint Fusion System. , SiCure is ... SiCure can be implanted in either a lateral or posterior approach, and is ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... UK Ltd (Bock) announced a strategic partnership where Bock will demonstrate DuPont’s ... OPTIMASH® AD-100, has been shown to help biogas producers in the agricultural sector ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Supplies of ... of leading experts gathered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) ... of technetium-99m (Tc-99m), which is used in 30 to 40 million nuclear medicine procedures ...
(Date:6/27/2017)... ... June 27, 2017 , ... The recent vote by the American Medication ... gives new hope to patients and hopefully sheds new light on the way health ... an infertility expert and founding partner of Texas Fertility Center . , ...
Breaking Biology Technology: